Phase II study of bevacizumab in combined with carboplatin plus pemetrexed for patients with untreated non-squamous non-small cell lung cancer with brain metastases.
- Conditions
- non-squamous non-small cell lung cancer
- Registration Number
- JPRN-UMIN000013010
- Lead Sponsor
- International University of Health and Werfare, Respiratory Disease Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 38
Not provided
1) Antiedema agent treatment for a brain metastasis 2) Bleeding of the brain metastasis 3) Carcinomatous meningitis 4) Squamous cell dominant 5) Small cell lung carcinoma cells are contained. 6) Cerebral amyloid angiopathy 7) Current or previous history of hemoptysis 8) Current or previous history of continuing bloody sputum - History of continuing bloody sputum within 3 months - Current or previous history of continuing taking a oral hemostatic agent - Need to treat intravenous hemostatic agent for sputum 9) Have received radiation therapy to lesions of the lung 10) Have received therapy to primary lesion 11) Evidence of tumor invading large vessel on imaging 12) Severe infection 13) Severe complications 14) Uncontrolled ascites, pleural effusion or pericardial effusion 15) Active concomitant malignancy 16) History of severe drug allergy 17) Active interstitial pneumonitis or pulmonary fibrosis on chest CT scans 18) Uncontrollable hypertension < 160/100 19) History of symptomatic cerebrovascular disease 20) Need to antiplatelet therapy or anticoagulation therapy without Aspirin 325 mg/day 21) Uncontrolled ulcer 22) Gastrointestinal perforation within 1 year 23) Inappropriate for this study judged by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method